Zoetis has been granted a conditional license by the US Department of Agriculture (USDA) for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is designed to protect chickens against Highly Pathogenic Avian Influenza (HPAI), which has affected over 150 million birds in the US since February 2022.
The conditional license was issued based on the demonstration of safety, purity, and a reasonable expectation of efficacy from serology data. Zoetis is committed to supporting poultry producers with scientific solutions for HPAI.
“This latest vaccine update demonstrates our commitment to advancing care for animals and addressing global animal health challenges,” said Mahesh Kumar, senior vice president of global biologics research and development at Zoetis.
Zoetis has a long history of developing vaccines against avian influenza in multiple countries. The company’s H5N1 vaccine was first used by the US Fish & Wildlife Service to protect California condors in 2023, while its POULVAC FLUFEND i AI H5N3 RG vaccine helped protect endangered birds in New Zealand in 2024.
The conditional license is a finite period measure that can be renewed at the CVB’s discretion. Zoetis will continue to work with regulatory authorities and the poultry industry to support vaccination efforts against HPAI.
Source: https://www.businesswire.com/news/home/20250214307661/en/Zoetis-Receives-Conditional-License-from-USDA-for-Avian-Influenza-Vaccine-H5N2-Subtype-Killed-Virus